{
    "title": "Biogen, Sage face uphill battle with postpartum depression pill",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-12380785/Biogen-Sage-face-uphill-battle-postpartum-depression-pill.html",
    "date": "2023-08-07",
    "keywords": [
        "depression",
        "biogen",
        "drug",
        "approval",
        "ppd",
        "bhanvi",
        "satija",
        "mariam",
        "sage",
        "fda",
        "price",
        "zurzuvae",
        "treatment",
        "use",
        "analyst",
        "skorney",
        "latestage",
        "opportunity",
        "mdd",
        "pill",
        "growth",
        "commentary",
        "food",
        "administration",
        "premarket",
        "trading",
        "complication",
        "pregnancy",
        "ability",
        "decision",
        "cohort",
        "safety",
        "strike",
        "management",
        "baird",
        "indication",
        "market",
        "premium",
        "research",
        "note",
        "need",
        "effect",
        "trial",
        "zurzuvaes",
        "postpartum",
        "ceo",
        "christopher",
        "viehbacher",
        "month",
        "week",
        "disorder",
        "study",
        "focus",
        "announcement",
        "job",
        "yee",
        "reporting",
        "sunny",
        "bengaluru",
        "writing",
        "vinay",
        "dwivedi"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}